Financials data is unavailable for this security.
View more
Year on year Sinovac Biotech Ltd 's revenues fell -69.97% from 1.49bn to 448.27m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 113.87m to a loss of 99.92m.
| Gross margin | 92.09% |
|---|---|
| Net profit margin | -69.19% |
| Operating margin | -103.87% |
| Return on assets | -2.23% |
|---|---|
| Return on equity | -1.51% |
| Return on investment | -3.30% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Sinovac Biotech Ltd fell by 3.01bn. However, the company earned 104.00m from its operations for a Cash Flow Margin of 23.20%. In addition the company used 2.92bn on investing activities and also paid 76.06m in financing cash flows.
| Cash flow per share | -1.74 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 86.81 |
|---|---|
| Tangible book value per share | 86.73 |
More ▼
Balance sheet in USDView more
| Current ratio | 11.39 |
|---|---|
| Quick ratio | 11.24 |
| Total debt/total equity | 0.0358 |
|---|---|
| Total debt/total capital | 0.0262 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items dropped -212.51%.
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 63.89 |
